240 related articles for article (PubMed ID: 28100259)
21. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells.
Cho CY; Huang JS; Shiah SG; Chung SY; Lay JD; Yang YY; Lai GM; Cheng AL; Chen LT; Chuang SE
RNA; 2016 Feb; 22(2):303-15. PubMed ID: 26667302
[TBL] [Abstract][Full Text] [Related]
22. miR-34a Promotes Vascular Smooth Muscle Cell Calcification by Downregulating SIRT1 (Sirtuin 1) and Axl (AXL Receptor Tyrosine Kinase).
Badi I; Mancinelli L; Polizzotto A; Ferri D; Zeni F; Burba I; Milano G; Brambilla F; Saccu C; Bianchi ME; Pompilio G; Capogrossi MC; Raucci A
Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):2079-2090. PubMed ID: 30026277
[TBL] [Abstract][Full Text] [Related]
23. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
24. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
Wu X; Cheng YL; Matthen M; Yoon A; Schwartz GK; Bala S; Taylor AM; Momen-Heravi F
J Exp Clin Cancer Res; 2021 Feb; 40(1):70. PubMed ID: 33596979
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met.
Yan D; Zhou X; Chen X; Hu DN; Dong XD; Wang J; Lu F; Tu L; Qu J
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1559-65. PubMed ID: 19029026
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
Li Y; Guessous F; Zhang Y; Dipierro C; Kefas B; Johnson E; Marcinkiewicz L; Jiang J; Yang Y; Schmittgen TD; Lopes B; Schiff D; Purow B; Abounader R
Cancer Res; 2009 Oct; 69(19):7569-76. PubMed ID: 19773441
[TBL] [Abstract][Full Text] [Related]
28. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-31 inhibits lung adenocarcinoma stem-like cells via down-regulation of MET-PI3K-Akt signaling pathway.
Hou C; Sun B; Jiang Y; Zheng J; Yang N; Ji C; Liang Z; Shi J; Zhang R; Liu Y; Ye C; Zuo P
Anticancer Agents Med Chem; 2016; 16(4):501-18. PubMed ID: 26299665
[TBL] [Abstract][Full Text] [Related]
30. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
31. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
32. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
33. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
34. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.
Cao W; Yang W; Fan R; Li H; Jiang J; Geng M; Jin Y; Wu Y
Tumour Biol; 2014 Feb; 35(2):1287-95. PubMed ID: 24068565
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL.
Nam RK; Benatar T; Wallis CJD; Kobylecky E; Amemiya Y; Sherman C; Seth A
Prostate; 2019 Sep; 79(12):1422-1438. PubMed ID: 31269290
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
[TBL] [Abstract][Full Text] [Related]
37. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
[TBL] [Abstract][Full Text] [Related]
39. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
40. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
